Page 17 - Nasdaq First News Today

2022-09-26 PRESSRELEASE Arcoma wins tender of 10 million SEK to Czech Republic Arcoma AB has won a tender of 5 Arcoma Precision i5 systems to “Prague...

Investegate announcements from Faron Pharma. Oy, Grant of Options

> Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally > Cash position of €26.9 million as of June 30, 2022 > Financial visibility assured until Q2 2023 Regulatory

PARIS--(BUSINESS WIRE)--Regulatory News:Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR)n in particular against rare or resistant forms of cancer, today announced that...

Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage

24.08.2022 - 2022-08-24 PRESSRELEASE Arcoma receives order of 8 systems to Thailand Arcoma AB has received an order of 8 X-ray systems to Thailand. The total order value is approximately 5-6 MSEK and the systems will be installed during Q3 2022 - Q1 2023. ...

Company to submit delisting request to Nasdaq Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development

Investegate announcements from Faron Pharma. Oy, Results of EGM

2022-07-07 PRESSRELEASE Arcoma Precision i5 approved for sales in Singapore Arcoma has many installations in Singapore and we are, together with our distributor QST Technologies Pte Ltd an

Investegate announcements from Arcoma AB, Arcoma Precision i5 approved for sales in Singapore